56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy

Chronic Kidney Disease: Definition, Etiologies & The KDIGO 2024 Staging Grid

Chronic Kidney Disease (CKD) represents a major global public health challenge affecting more than 10% of the worldwide adult population. It is defined pathologically and physiologically by abnormalities of kidney structure or function present for greater than 3 months, with documented implications for systemic health.

Diagnostic Criteria for CKD

Under Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, a patient meets the diagnostic threshold for CKD if either of the following criteria persists for >3 months:

1. Decreased Glomerular Filtration Rate: Estimated Glomerular Filtration Rate (eGFR) < 60 mL/min/1.73 m² (calculated using the standardized 2021 CKD-EPI creatinine equation without race coefficients).
2. Markers of Kidney Damage (one or more):
   • Persistent Albuminuria: Urine Albumin-to-Creatinine Ratio (UACR >= 30 mg/g [or >= 3 mg/mmol]) on at least two of three spot urine specimens collected over a 3- to 6-month period.
   • Urine Sediment Abnormalities: Persistent dysmorphic red blood cells (RBCs), red blood cell casts (pathognomonic for glomerulonephritis), white blood cell casts (tubulointerstitial nephritis), or oval fat bodies (nephrotic syndrome).
   • Electrolyte and Tubular Disorders: Renal tubular acidosis, nephrogenic diabetes insipidus, or persistent renal potassium wasting.
   • Histopathologic Abnormalities: Documented on percutaneous renal biopsy (e.g., glomerulosclerosis, amyloidosis, IgA deposition).
   • Structural Imaging Abnormalities: Polycystic kidney disease, severe hydronephrosis, medullary sponge kidney, renal cortical thinning, or asymmetric atrophic kidneys on ultrasound or CT.
   • History of Kidney Transplantation.

                      KDIGO 2024 2-DIMENSIONAL STAGING GRID

   eGFR Category (mL/min/1.73 m²)        Albuminuria Category (UACR in mg/g)
   ══════════════════════════════════    ═══════════════════════════════════════════════════
   G1: Normal or high (>= 90)            A1: Normal to mildly increased (< 30 mg/g)
   G2: Mildly decreased (60 - 89)        A2: Moderately increased (30 - 299 mg/g) [Micro]
   G3a: Mild-to-moderate (45 - 59)       A3: Severely increased (>= 300 mg/g)     [Macro]
   G3b: Moderate-to-severe (30 - 44)     ───────────────────────────────────────────────────
   G4: Severely decreased (15 - 29)      *Nephrotic-Range Proteinuria: UACR > 2000-3000 mg/g
   G5: Kidney failure (< 15 or Dialysis)  (accompanied by serum albumin < 3.0 g/dL, edema)
   ══════════════════════════════════    ═══════════════════════════════════════════════════

The KDIGO Heat Map: Prognostic Risk Stratification

Staging requires both the eGFR category (G1 to G5) and the persistent albuminuria category (A1 to A3). Albuminuria is a potent, independent predictor of cardiovascular events, all-cause mortality, and end-stage kidney disease (ESKD), even among patients with preserved filtration rates (G1-G2).

                   KDIGO PROGNOSTIC RISK HEAT MAP MATRIX

   eGFR Categories                       Persistent Albuminuria Categories
   (mL/min/1.73 m²)                      A1 (< 30 mg/g)   A2 (30-299 mg/g)   A3 (>= 300 mg/g)
   ═══════════════════════════════════════════════════════════════════════════════════════════
   G1 (>= 90)     Normal / High          Low Risk         Moderate Risk      High Risk
   G2 (60 - 89)   Mildly Decreased       Low Risk         Moderate Risk      High Risk
   G3a (45 - 59)  Mild-to-Moderate       Moderate Risk    High Risk          Very High Risk
   G3b (30 - 44)  Moderate-to-Severe     High Risk        Very High Risk     Very High Risk
   G4 (15 - 29)   Severely Decreased     Very High Risk   Very High Risk     Very High Risk
   G5 (< 15)      Kidney Failure         Very High Risk   Very High Risk     Very High Risk
   ═══════════════════════════════════════════════════════════════════════════════════════════
   *Outcomes predicted: All-cause mortality, CV mortality, CKD progression, acute kidney injury.

• Clinical Note on Terminology: The historical terms "microalbuminuria" (30-299 mg/g) and "macroalbuminuria" (>=300 mg/g) have been replaced in modern guidelines by moderately increased (A2) and severely increased (A3) albuminuria to emphasize that albumin excretion represents a continuous, graded biological spectrum of vascular injury rather than arbitrary cutoffs.

Quadruple Renoprotective Pharmacotherapy: The 4 Disease-Modifying Pillars

Historically, kidney protection was limited to glycemic control and blood pressure lowering with ACE inhibitors. Today, clinical trial evidence has established a quadruple disease-modifying pharmacotherapy platform that dramatically slows CKD progression, delays ESKD, and prevents cardiovascular death.

                 THE 4 PILLARS OF RENOPROTECTIVE PHARMACOTHERAPY

   Pillar                 Drug Class & Representative Agents      Primary Clinical Indication
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Pillar 1: RAAS Block   ACEi (Lisinopril, Enalapril, Ramipril)  CKD with Hypertension AND
                          OR ARB (Losartan, Valsartan)            Albuminuria (UACR >= 30 mg/g)

   Pillar 2: SGLT2i       Dapagliflozin 10 mg PO daily            CKD with eGFR 20-60 mL/min and
                          Empagliflozin 10 mg PO daily            UACR >= 200 mg/g (± Diabetes)

   Pillar 3: nsMRA        Finerenone 10 to 20 mg PO daily         Type 2 Diabetes with CKD and
                                                                  persistent UACR >= 30 mg/g

   Pillar 4: GLP-1 RA     Semaglutide 1.0 mg SC weekly            Type 2 Diabetes with CKD at high
                                                                  risk for CVD or CKD progression
   ═════════════════════════════════════════════════════════════════════════════════════════════

Pillar 1: Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors

• Mechanisms of Action & Hemodynamics:
  • Angiotensin II preferentially constricts the efferent arteriole of the glomerulus. In diabetic and hypertensive nephropathy, elevated local angiotensin II levels increase intraglomerular hydraulic pressure, stretching the capillary basement membrane and podocytes, driving hyperfiltration and proteinuria.
  • ACE inhibitors and ARBs block angiotensin II generation or binding, inducing preferential vasodilation of the efferent arteriole. This decompresses the glomerular capillary bed, reducing intraglomerular hypertension and slowing long-term glomerulosclerosis.
• The Expected Hemodynamic Creatinine Rise: The 30% Rule:
  • Because efferent arteriolar vasodilation lowers glomerular filtration pressure, an acute, mild reduction in eGFR occurs within 2 to 4 weeks of starting or uptitrating an ACEi or ARB.
  • The Clinical Pearl: An acute increase in serum creatinine of up to 30% from baseline (or a drop in eGFR of up to 25%) within 2 to 4 weeks of initiation is an expected, benign hemodynamic effect. It proves the drug is successfully decompressing the glomerulus and is correlated with superior long-term nephron preservation!
  • Management Rule: Do NOT discontinue or reduce the dose of the ACEi/ARB if the creatinine rise is <=30%, provided serum potassium remains <=5.5 mEq/L. Recheck labs in 4 to 8 weeks.
  • When to Intervene: If serum creatinine increases by > 30%, immediately pause the ACEi/ARB and evaluate for reversible causes of renal hypoperfusion: bilateral renal artery stenosis (or stenosis in a solitary kidney), severe intravascular volume depletion (diuretic overdiuresis, vomiting, diarrhea), or concurrent use of NSAIDs (which constrict the afferent arteriole, creating a double hemodynamic hit).
• The Absolute Prohibition Against Dual RAAS Blockade:
  • NEVER combine an ACE inhibitor with an ARB (or combine either with the direct renin inhibitor aliskiren).
  • The landmark ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D randomized controlled trials established that dual ACEi + ARB combination therapy provided no incremental benefit in slowing CKD progression or reducing cardiovascular mortality, but produced a dramatic, statistically significant increase in severe adverse events: hyperkalemia, acute kidney injury (AKI), and symptomatic syncope/hypotension.

Pillar 2: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

• Representative Agents & Dosing: Dapagliflozin 10 mg PO once daily; Empagliflozin 10 mg PO once daily; Canagliflozin 100 mg PO once daily.
• Pivotal Trial Evidence:
  • DAPA-CKD Trial: Enrolled patients with eGFR 25 to 75 mL/min/1.73 m² and UACR 200 to 5,000 mg/g (with or without Type 2 Diabetes). Dapagliflozin reduced the composite risk of sustained >=50% eGFR decline, ESKD, or renal/CV death by 39% (HR 0.61; NNT = 19).
  • EMPA-KIDNEY Trial: Expanded inclusion down to an eGFR of 20 mL/min/1.73 m² and included patients with normal-to-mild albuminuria. Empagliflozin reduced kidney disease progression or CV death by 28% (HR 0.72).
• The Game-Changing Board Rule: SGLT2 inhibitors confer profound renoprotective and cardioprotective benefits independent of diabetes! They are indicated for non-diabetic CKD (e.g., ischemic nephrosclerosis, IgA nephropathy, focal segmental glomerulosclerosis) as well as diabetic kidney disease.
• Hemodynamic & Cellular Mechanism:
  • SGLT2 inhibitors block sodium and glucose reabsorption in the proximal convoluted tubule.
  • Increased delivery of sodium and chloride to the distal macula densa restores impaired tubuloglomerular feedback (TGF).
  • The macula densa releases adenosine, which binds to $A_1$ receptors on the adjacent afferent arteriole, causing afferent arteriolar vasoconstriction.
  • This afferent constriction reduces intraglomerular hyperfiltration, offloading glomerular wall stress.
  • Note the synergy: SGLT2 inhibitors constrict the afferent arteriole, while ACEi/ARBs dilate the efferent arteriole; combined, they maximally restore physiological intraglomerular pressure.
• Initiation & Continuation Thresholds:
  • May be initiated down to an eGFR of 20 mL/min/1.73 m².
  • Once initiated, SGLT2 inhibitors should be continued until the patient transitions to maintenance chronic dialysis or receives a kidney transplant, even if eGFR subsequently falls below 20 mL/min/1.73 m².
• Safety & Side Effect Profile:
  • Expect an initial reversible "hemodynamic dip" in eGFR of 3 to 5 mL/min within the first 2 to 4 weeks, which stabilizes and preserves long-term renal function.
  • Increased risk of mycotic genital infections (candidal balanitis, vulvovaginitis; easily managed with topical antifungals without stopping therapy).
  • Rare risk of euglycemic diabetic ketoacidosis (euDKA) in patients with diabetes during periods of acute stress, surgery, or starvation (instruct patients to withhold SGLT2i 3 to 4 days prior to elective major surgery).

Pillar 3: Non-Steroidal Mineralocorticoid Receptor Antagonists (nsMRAs)

• Representative Agent: Finerenone (starting dose 10 mg or 20 mg PO daily based on baseline eGFR [10 mg if eGFR 25-59; 20 mg if eGFR >=60 mL/min/1.73 m²]).
• Landmark Evidence (FIDELIO-DKD & FIGARO-DKD Trials):
  • Demonstrated that finerenone significantly reduced the primary composite kidney outcome (ESKD, sustained >=40% eGFR decline, renal death) and major adverse cardiovascular events (CV death, non-fatal MI, heart failure hospitalization) in patients with Type 2 Diabetes and CKD treated with background maximally tolerated ACEi or ARB therapy.
• Mechanism: Traditional steroidal MRAs (spironolactone, eplerenone) carry high risks of severe hyperkalemia and endocrine side effects (gynecomastia). Finerenone is a non-steroidal, highly selective MRA that binds the mineralocorticoid receptor with high affinity, potently suppressing aldosterone-mediated pro-inflammatory and pro-fibrotic gene transcription in both renal podocytes and vascular smooth muscle without altering sex hormone receptors.
• Potassium Safety Monitoring:
  • Measure serum potassium and eGFR prior to initiation. Baseline serum potassium must be <= 4.8 to 5.0 mEq/L to start.
  • Recheck potassium at 4 weeks post-initiation and periodically thereafter.
  • Hold finerenone if potassium exceeds 5.5 mEq/L; resume at 10 mg once potassium normalizes to <=5.0 mEq/L.

Pillar 4: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

• Representative Agent: Semaglutide (titrated up to 1.0 mg SC weekly) or Dulaglutide.
• Landmark Evidence (The FLOW Trial):
  • The Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial enrolled 3,533 patients with Type 2 Diabetes and CKD (eGFR 50-75 with UACR >300-5000 mg/g, or eGFR 25-49 with UACR >100-5000 mg/g).
  • The trial was stopped early for overwhelming positive efficacy: Semaglutide 1.0 mg weekly reduced the primary composite endpoint (kidney failure, sustained >=50% eGFR loss, or death from kidney/CV causes) by 24% (HR 0.76; p = 0.0003), accompanied by an 18% reduction in major adverse cardiovascular events (MACE) and a 20% reduction in all-cause mortality.
• Clinical Application: Indicated in patients with T2D and CKD who have persistent albuminuria or elevated cardiovascular risk, providing potent glycemic control, blood pressure reduction, sustained weight reduction, and direct anti-inflammatory renal benefits without intrinsic hypoglycemia risk.

Blood Pressure Targets, Lipid Guidelines & Nephrology Referral Criteria

Comprehensive management of chronic kidney disease extends beyond kidney-specific therapies to aggressive cardiovascular risk reduction, as patients with CKD are exponentially more likely to die from cardiovascular disease than to survive to reach dialysis.

Blood Pressure Targets in CKD (KDIGO 2021/2024)

• Standardized Target: KDIGO guidelines recommend targeting a standardized office Systolic Blood Pressure (SBP) < 120 mmHg in adults with CKD, using standardized automated office blood pressure measurement techniques.
• Clinical Evidence: Supported by the CKD subgroup analysis of the landmark SPRINT trial, which demonstrated that intensive SBP lowering to <120 mmHg significantly reduced all-cause mortality and major cardiovascular events compared to standard targets (<140 mmHg), without accelerating permanent loss of kidney function.
• Practical Qualification: If automated standardized measurement is unavailable, or if the patient experiences symptomatic orthostatic hypotension, frailty, or advanced dementia, a clinical target of < 130/80 mmHg remains acceptable.
• Pharmacologic Hierarchy for Hypertension in CKD:
  1. First-line in patients with UACR >= 30 mg/g: ACE inhibitor or ARB titrated to maximum recommended or tolerated dose.
  2. Second-line / Add-on therapy: Long-acting dihydropyridine calcium channel blockers (Amlodipine 5 to 10 mg daily) or SGLT2 inhibitors.
  3. Third-line: Diuretics to counter renal sodium retention. Use thiazide-like diuretics (Chlorthalidone 12.5-25 mg daily or Indapamide) if eGFR >= 30 mL/min/1.73 m²; transition to loop diuretics (Furosemide, Torsemide, Bumetanide) when eGFR falls below 30 mL/min/1.73 m².

Statin Therapy & Cardiovascular Risk Reduction (KDIGO Lipid Guidelines)

Patients with CKD exhibit accelerated atherogenesis driven by oxidative stress, chronic inflammation, and endothelial dysfunction. However, lipid management in CKD follows unique, evidence-based rules that differ sharply from the general population:

                  KDIGO STATIN THERAPY PROTOCOL IN CKD

   Clinical Patient Population            Recommended Lipid Management Strategy
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Age >= 50 years, CKD G1-G5             Initiate Statin Monotherapy (e.g., Atorvastatin 20 mg)
   (NOT on chronic dialysis)              OR Statin + Ezetimibe 10 mg daily. (No LDL target!)

   Age 18 - 49 years, CKD G1-G5           Initiate Statin if one or more high-risk features:
   (NOT on chronic dialysis)              Known CAD, Diabetes, Prior Stroke, or 10-yr ASCVD >10%

   Patients ALREADY taking a statin       CONTINUE statin therapy across the transition
   when initiating chronic dialysis       onto maintenance dialysis.

   Patients ALREADY on maintenance        DO NOT INITIATE de novo statin therapy!
   chronic hemodialysis or peritoneal     (Proven ineffective for reducing mortality in
   dialysis WITHOUT prior statin use      the landmark 4D and AURORA clinical trials)
   ═════════════════════════════════════════════════════════════════════════════════════════════

• The "Fire and Forget" Principle: In CKD, statin therapy is prescribed based on cardiovascular risk rather than titrating to specific LDL-cholesterol targets. Routine serial lipid panels are not required once therapy is established unless assessing compliance.
• The Dialysis Paradox Explained: Two large prospective randomized trials—4D (Die Deutsche Diabetes Dialyse Studie; atorvastatin 20 mg in diabetic hemodialysis patients) and AURORA (rosuvastatin 10 mg in end-stage renal disease)—demonstrated that statin therapy failed to reduce the primary composite endpoint of cardiovascular death, non-fatal MI, or stroke in maintenance hemodialysis patients. In end-stage renal disease, cardiovascular mortality is overwhelmingly non-atherosclerotic (sudden cardiac death from fatal ventricular arrhythmias, hyperkalemia, and calcific heart failure) rather than plaque rupture. Therefore, de novo statins are never initiated once a patient is dialysis-dependent.

Criteria for Mandatory Nephrology Referral

Primary care physicians manage the vast majority of patients with early-stage CKD. Timely nephrology referral before end-stage disease develops is critical for vascular access planning (arteriovenous fistula placement), preemptive kidney transplant evaluation, and metabolic stabilization.

                    CRITERIA FOR NEPHROLOGY REFERRAL

   Clinical Trigger                       Specific Diagnostic Cutoff / Presentation
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Advanced Renal Impairment              eGFR < 30 mL/min/1.73 m² (KDIGO Stage G4 or G5)

   Severe Albuminuria                     Persistent UACR >= 300 mg/g (or protein >= 300 mg/24h)

   Rapid Progression                      Sustained eGFR decline > 5 mL/min/1.73 m² per year
                                          OR > 10 mL/min/1.73 m² over 3 years

   Active Glomerular Sediment             Unexplained microscopic hematuria with > 5 RBCs/HPF,
                                          dysmorphic red blood cells, or RBC casts

   Refractory Hypertension                Blood pressure above goal despite >= 4 concurrent
                                          antihypertensive agents at optimal doses

   Unexplained Metabolic Derangements     Persistent hyperkalemia, secondary hyperparathyroidism,
                                          recurrent nephrolithiasis, or hereditary kidney disease
   ═════════════════════════════════════════════════════════════════════════════════════════════